A. Kojima

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Y. Bang, N. Sugimoto, D. Sakai, 2020 .

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Y. Bang, N. Sugimoto, D. Sakai, 2020, The New England journal of medicine.

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Y. Bang, N. Sugimoto, D. Sakai, 2020 .

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Y. Bang, N. Sugimoto, Keun-Wook Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Y. Bang, N. Sugimoto, D. Sakai, 2021 .

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Y. Bang, N. Sugimoto, D. Sakai, 2022, Journal of Clinical Oncology.

O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma

N. Sugimoto, D. Sakai, M. Ryu, 2021, Annals of Oncology.